Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment.

Abstract:

:Glaucoma, a group of progressive optic neuropathies with similar patterns of tissue loss, is primarily treated with medical therapy, followed by laser therapy and, later, incisional surgery. Aside from the introduction of prostaglandin analogs, topical carbonic anhydrase inhibitors, and topical alpha-agonists in the 1990s, no new pharmaceutical agents to lower intraocular pressure (IOP) have been introduced for approximately 20 years. The Rho kinase inhibitors represent a new class of glaucoma medications that inhibit the downstream pathway of the Rho family of small G-proteins to increase outflow from the conventional (trabecular) outflow pathway in the eye. Several of these Rho kinase inhibitors, ripasudil and netarsudil, have recently reached the market and are used in clinical practice in several countries. A fixed-dose combination of latanoprost and netarsudil was also very recently approved (2019) by the US FDA. Several other novel agents are undergoing clinical trials. These drugs are poised to act as adjuncts to already established medical therapy for further lowering of IOP in the treatment of glaucoma.

journal_name

Drugs

journal_title

Drugs

authors

Schehlein EM,Robin AL

doi

10.1007/s40265-019-01130-z

subject

Has Abstract

pub_date

2019-07-01 00:00:00

pages

1031-1036

issue

10

eissn

0012-6667

issn

1179-1950

pii

10.1007/s40265-019-01130-z

journal_volume

79

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Therapeutic experience with temocillin in peritonitis.

    abstract::The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. Patients were treated with temocillin Ig intravenously twice daily. The isolated pathogens comprised mainly Escherichia co...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00042

    authors: Pfeiffer M,Fock RR

    更新日期:1985-01-01 00:00:00

  • Danoprevir: First Global Approval.

    abstract::Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0960-0

    authors: Markham A,Keam SJ

    更新日期:2018-08-01 00:00:00

  • Influence of fibrinogen on cardiovascular disease.

    abstract::Results from prevalence, case-control, angiographic and echocardiographic investigations incriminate elevated fibrinogen levels as a strong independent risk factor for the occurrence of initial and recurrent cardiovascular events. Average fibrinogen levels are higher in women and persons with other risk factors includ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700543-00006

    authors: Kannel WB

    更新日期:1997-01-01 00:00:00

  • Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.

    abstract::Matrix metalloproteinases (MMPs) are a family of functionally related zinc-containing enzymes that denature and degrade fibrillar collagens and other components of the extracellular matrix. Myocardial extracellular matrix remodelling and fibrosis regulated by MMPs are believed to be important contributors to the progr...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161090-00002

    authors: Li YY,Feldman AM

    更新日期:2001-01-01 00:00:00

  • Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.

    abstract::Chenodeoxycholic acid (chenic acid; CDCA) is 1 of the 3 major biliary bile acids in man. When administered in pharmacological doses it causes a decrease in cholesterol saturation of bile, which in turn may lead to gradual dissolution of cholesterol gallstones. The stone dissolution rate during CDCA therapy has varied ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198121020-00002

    authors: Iser JH,Sali A

    更新日期:1981-02-01 00:00:00

  • Gatifloxacin: a review of its use in the management of bacterial infections.

    abstract:UNLABELLED:Gatifloxacin is an 8-methoxy fluoroquinolone antibacterial agent. The drug has a broader spectrum of antibacterial activity than the older fluoroquinolones (e.g. ciprofloxacin) and shows good activity against many Gram-positive and Gram-negative pathogens, atypical organisms and some anaerobes. Notably, gati...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262010-00007

    authors: Perry CM,Ormrod D,Hurst M,Onrust SV

    更新日期:2002-01-01 00:00:00

  • Fluoroquinolones and surgical prophylaxis.

    abstract::The objective of surgical prophylaxis is to prevent wound infections associated with surgery. The rates of wound infections vary according to the procedure: less than 3 infections per 100 for clean procedures; up to 4 per 100 for clean-contaminated procedures; and up to 9 per 100 for contaminated procedures. Surgical ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300453-00018

    authors: Dellamonica P,Bernard E

    更新日期:1993-01-01 00:00:00

  • The sore throat. When to investigate and when to prescribe.

    abstract::Sore throats are most commonly due to infections, many of which are viral and do not require specific treatment. Symptoms and signs of the common cold, influenza or croup, the occurrence of conjunctivitis in some adenoviral infections, generalised lymphadenopathy and splenomegaly in glandular fever or the presence of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040060-00007

    authors: Lang SD,Singh K

    更新日期:1990-12-01 00:00:00

  • Dexamethasone in adults with community-acquired bacterial meningitis.

    abstract::Bacterial meningitis in adults is a severe disease with high fatality and morbidity rates. Experimental studies have shown that the inflammatory response in the subarachnoid space is associated with an unfavourable outcome. In these experiments, corticosteroids, and in particular dexamethasone, were able to reduce the...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666040-00002

    authors: van de Beek D,de Gans J

    更新日期:2006-01-01 00:00:00

  • Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

    abstract::Resting heart rate is associated with cardiovascular and all-cause mortality, and the mortality benefit of some cardiovascular drugs seems to be related in part to their heart rate-lowering effects. Since it is difficult to separate the benefit of heart rate lowering from other actions with currently available drugs, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464160-00003

    authors: DiFrancesco D,Camm JA

    更新日期:2004-01-01 00:00:00

  • Enoxaparin. A review of its clinical potential in the management of coronary artery disease.

    abstract:UNLABELLED:Enoxaparin (enoxaparin sodium) is a low molecular weight heparin (LMWH) that is widely used in the prevention of deep venous thrombosis and pulmonary embolism in patients undergoing orthopaedic or general surgery. Its efficacy in these indications has led to study of its use in patients with coronary artery ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856020-00013

    authors: Noble S,Spencer CM

    更新日期:1998-08-01 00:00:00

  • Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.

    abstract::Alectinib (Alecensa(®)) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK). Alectinib is approved for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0329-y

    authors: McKeage K

    更新日期:2015-01-01 00:00:00

  • Uraemic pruritus: clinical characteristics, pathophysiology and treatment.

    abstract::Pruritus is a common complication of end-stage renal disease (ESRD), affecting about one-third of dialysis patients. It is a chronic, unpleasant symptom with a strong negative impact on patients' quality of life, often inducing sleeplessness and mood disorders. Recent data show that it is also associated with increase...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969030-00002

    authors: Manenti L,Tansinda P,Vaglio A

    更新日期:2009-01-01 00:00:00

  • Pathophysiology and treatment of hepatitis C.

    abstract::Hepatitis C virus (HCV) infection is associated with a variable disease course and response to therapy. Some infected patients may develop little or no disease for 30 to 40 years, whereas others will develop cirrhosis within 5 to 10 years. Both host and viral factors influence the rate of disease progression. The mana...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199600522-00003

    authors: Thomas HC,Booth J,Brown J

    更新日期:1996-01-01 00:00:00

  • Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

    abstract::Nadroparin calcium is a low molecular weight heparin with a mean molecular weight of 4.5 kD. Compared with unfractionated heparin, nadroparin calcium has a greater ratio of anti-factor Xa/anti-factor IIa activity. Nadroparin calcium has a longer half-life and greater bioavailability than unfractionated heparin and can...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199244050-00010

    authors: Barradell LB,Buckley MM

    更新日期:1992-11-01 00:00:00

  • Risk factors for the spread of antibiotic-resistant bacteria.

    abstract::The emergence of antibiotic resistance is primarily due to excessive and often unnecessary use of antibiotics in humans and animals. Risk factors for the spread of resistant bacteria in hospitals and the community can be summarised as over-crowding, lapses in hygiene or poor infection control practices. Increasing ant...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855030-00001

    authors: Rao GG

    更新日期:1998-03-01 00:00:00

  • Traditional management of liver disorders.

    abstract::Dietary measures have achieved mixed results in the management of liver disorders. Although a high energy diet may shorten the course of viral hepatitis by a relatively small amount, dietary restriction is usually of no benefit in compensated cirrhosis. Restriction of sodium intake to 22 to 60 mol/day leads to resolut...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199000403-00005

    authors: Messner M,Brissot P

    更新日期:1990-01-01 00:00:00

  • Guide to the use of proton pump inhibitors in adult patients.

    abstract::Proton Pump Inhibitors (PPIs) are widely used in the treatment of acid-peptic diseases. Their mechanism of action involves inhibition of the H-K-adenosine triphosphatase enzyme present in the parietal cells of the gastric mucosa. Because PPIs are the most potent inhibitors of gastric acid secretion available, they eff...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868070-00004

    authors: Boparai V,Rajagopalan J,Triadafilopoulos G

    更新日期:2008-01-01 00:00:00

  • The coming era of quadrivalent human influenza vaccines: who will benefit?

    abstract::Influenza vaccines form the mainstay of public health and personal protection against infection with seasonal influenza viruses. These vaccines are designed to protect people against infection with the currently circulating influenza viruses. Since the late 1970s, this has required the use of a trivalent vaccine consi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11641110-000000000-00000

    authors: Barr IG,Jelley LL

    更新日期:2012-12-03 00:00:00

  • Acute upper gastrointestinal bleeding.

    abstract::The treatment of acute upper gastrointestinal bleeding is becoming more dependent upon early diagnosis. For the majority of patients whose bleeding has stopped when they come to the physician's attention, treatment for peptic disorders remains the mainstay of therapy. For patients who present to the physician actively...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198937010-00007

    authors: Schaffner JA

    更新日期:1989-01-01 00:00:00

  • Quinupristin-dalfopristin.

    abstract::Quinupristin-dalfopristin (RP 59500) is an injectable streptogramin antibiotic. It possesses a wide spectrum of activity against Gram-positive bacteria including methicillin-resistant staphylococci, glycopeptide-resistant. Enterococcus faecium and penicillin-resistant pneumococci. Quinupristin-dalfopristin has activit...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652030-00006

    authors: Bryson HM,Spencer CM

    更新日期:1996-09-01 00:00:00

  • Fluticasone furoate: intranasal use in allergic rhinitis.

    abstract::Fluticasone furoate nasal spray is a new topical intranasal corticosteroid with enhanced affinity for the glucocorticoid receptor and low systemic exposure, which was recently approved in the US for the treatment of seasonal or perennial allergic rhinitis in adults and in children aged >or=2 years. Fluticasone furoate...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767130-00010

    authors: McCormack PL,Scott LJ

    更新日期:2007-01-01 00:00:00

  • Rabeprazole: a review of its use in acid-related gastrointestinal disorders.

    abstract::Rabeprazole is an inhibitor of the gastric proton pump. It causes dose-dependent inhibition of acid secretion and has a more rapid onset of action than omeprazole. Duodenal ulcers healed faster after treatment with rabeprazole 20 or 40 mg/day than placebo or ranitidine 150 mg 4 times daily and at a generally similar r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958040-00014

    authors: Langtry HD,Markham A

    更新日期:1999-10-01 00:00:00

  • Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

    abstract::Aflibercept (Eylea(®)) is an anti-vascular endothelial growth factor agent indicated for intravitreal use in the treatment of diabetic macular oedema. In patients with diabetic macular oedema, significantly greater improvements from baseline to week 52 in visual acuity were seen with intravitreal aflibercept versus ma...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0421-y

    authors: Keating GM

    更新日期:2015-07-01 00:00:00

  • Impact of smoking on asthma therapy: a critical review of clinical evidence.

    abstract::Airway inflammation is central to the pathophysiology of asthma, with treatment directed towards modification of this inflammation and its consequences. The relationship between cigarette smoking and airway inflammation is also well described, but relatively little data are available on the potential influence of smok...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565110-00005

    authors: Livingston E,Thomson NC,Chalmers GW

    更新日期:2005-01-01 00:00:00

  • Elbasvir/Grazoprevir: First Global Approval.

    abstract::A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0558-3

    authors: Keating GM

    更新日期:2016-04-01 00:00:00

  • Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.

    abstract::Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0051-1

    authors: Keating GM

    更新日期:2013-05-01 00:00:00

  • Insulin glulisine: a review of its use in the management of diabetes mellitus.

    abstract::Insulin glulisine (Apidra) is a human insulin analogue approved for the improvement of glycaemic control in adults, adolescents and children with diabetes mellitus. It has similar binding properties, and is associated with a faster onset but similar level of glucose disposal, to regular human insulin (RHI). Insulin gl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969080-00006

    authors: Garnock-Jones KP,Plosker GL

    更新日期:2009-05-29 00:00:00

  • Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.

    abstract::Amorolfine is a structurally unique, topically active antifungal agent, which possesses both fungistatic and fungicidal activity in vitro. Its spectrum of in vitro activity includes dermatophyte, dimorphic, some dematiaceous and filamentous fungi, and some yeasts. In clinical trials, application of amorolfine 5% nail ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549010-00008

    authors: Haria M,Bryson HM

    更新日期:1995-01-01 00:00:00

  • Management of insomnia in patients with chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is a common medical disorder, which causes considerable morbidity and mortality. Given the chronic and symptomatic nature of the disease, the patient is often seen in the physician's office with complaints of dyspnea. However, more than 50% of COPD patients also have sleep ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363040-00004

    authors: George CF,Bayliff CD

    更新日期:2003-01-01 00:00:00